Penzymes Overview
- Status
-
Private
Penzymes General Information
Description
Developer of Selective Intracrine Modulators (SIMs) designed for the treatment of cancer. The company develops Selective Intracrine Modulators to block the local formation of steroid hormones in hormone-dependent malignancies of the prostate, breast, and endometrium, benefitting patients with castration-resistant prostate cancer (CRPC).
Contact Information
Website
www.penzymes.weebly.com
Ownership Status
Privately Held (no backing)
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Outcome Management (Healthcare)
Primary Office
- 3160 Chestnut Street
- Suite 200
- Philadelphia, PA 19104
- United States
Penzymes Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Trevor Penning Ph.D | Founder |